Lippe Robert A
Known title: Chief Operations OfficerCIK: 0001600757
Lippe Robert A's purchase track record
Lippe Robert A has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | LQDA | $9K | -13.0% | +28.8% | -0.1% |
| 5/24/2022 | LQDA | $100K | +116.6% | +42.4% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LQDA | ▲ Buy | Option Exercise | 1,718 | — | 11/30/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 497 | $4K | 11/30/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,719 | — | 8/31/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 505 | $3K | 8/31/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 597 | $5K | 5/31/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 1,719 | — | 5/31/2023 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,033 | $15K | 2/28/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 6,875 | — | 2/28/2023 | View on chart |
| LQDA | ▲ Buy | Grant | 83,333 | $0 | 1/11/2023 | View on chart |
| LQDA | ▲ Buy | Open Market | 1,918 | $9K | 8/31/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 29,628 | $100K | 5/24/2022 | View on chart |
| LQDA | ▼ Sell | Tax Withholding | 12,612 | $62K | 11/12/2021 | View on chart |
| LQDA | ▼ Sell | Tax Withholding | 518 | $3K | 11/12/2021 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 51,250 | — | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.